Target intelligence / Profile preview

Progestin and adipoQ receptor family member 9 (PAQR9)

Target
PAQR9
Molecular classification
Receptor, G protein-coupled receptor (predicted to act through G(s) pathway, and belongs to PAQR family), Plasma membrane protein
01

Overview

Progestin and adipoQ receptor family member 9 (PAQR9) is a putative G protein-coupled receptor, localized to the plasma membrane, and believed to mediate rapid signal transduction for progestins and neurosteroids such as progesterone, DHEA, allopregnanolone, pregnenolone, and pregnanolone. It is predicted to function via a G(s)-mediated pathway, participating in steroid hormone signaling especially within neural tissues. PAQR9 is implicated in endocrine, metabolic, and reproductive system functions and is associated with disease processes such as microvascular complications of diabetes and prostate carcinoma in situ. No drugs currently target PAQR9 directly, and its functional role is under ongoing investigation.

Other names
PAQR9Membrane progesterone receptor epsilon (mPRɛ)BLNC1
02

Mechanism of action

Ligand binding (progesterone and neurosteroids) activates G protein–mediated intracellular signaling (specifically G(s) pathway). Likely non-genomic steroid hormone signaling and regulation of neuronal processes.

03

Biological functions

Signal transduction (primarily for progestins and neurosteroids)Regulates rapid steroid (progesterone, DHEA, allopregnanolone) signaling in the nervous systemMay act upstream of egg chorion assembly (in model organisms)
04

Disease associations

Microvascular complications of diabetesProstate carcinoma in situPotential roles in reproductive and metabolic disorders (based on pathway and gene family)
05

Safety considerations

No safety concerns reported due to absence of clinical drugs targeting this receptorTheoretical concerns would be related to steroid hormone signaling modulation, but no clinical data currently available
06

Interacting drugs

progestins

5 more in the full profile.

07

Biomarkers

No established biomarkers for patient selection or efficacy monitoring specific to PAQR9Expression may potentially be monitored in reproductive or neurological disorders, candidate for further research

Beyond the preview

Go deeper on Progestin and adipoQ receptor family member 9 (PAQR9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progestin and adipoQ receptor family member 9 (PAQR9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call